Earnings
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, provides a trading update for the six month period ended 30 June 2019.
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Revenue and EBITDA for full year 2019 expected to be ahead of market expectations
Novartis saw a strong boost in sales during the second quarter, driven by Cosentyx and Entresto, as well as a 9% growth in oncology sales, the company announced this morning.
Adocia, the clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announces its financial results for the first six months ended June 30, 2019.
BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease
Allergy Therapeutics plc provides a trading update for the year ended 30 June 2019 ahead of its Preliminary Results to be announced on 25 September 2019.
Global, unaudited sales of HEMOBLAST™ Bellows for the first half of 2019 were €1.4 million – on track to achieve 2019 revenue guidance range of €4.0-4.5 million; projection for 15% market share in the US and main European countries remains a long-term goal
Biofrontera AG, an international biopharmaceutical company, reports preliminary unaudited revenue for the first six months of fiscal year 2019.
ADL Bionatur Solutions announced the expansion of the production agreement with a long-standing client, a global science-based company active in nutrition, health and sustainable living.
PRESS RELEASES